Kk Lee

Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease

Aim : To evaluate the economic impact of celecoxib therapy vs. diclofenac plus omeprazole therapy for the treatment of arthritis in Chinese patients with a high risk of bleeding, from the perspective of a public health organization in Hong Kong.

Economic analysis of four triple regimens for the treatment of Helicobacter pylori-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong.

One‐week triple regimens have been shown to be effective for the treatment of Helicobacter pylori‐related peptic ulcer disease.

PIN17 COST-EFFECTIVENESS OF PNEUMOCOCCAL VACCINATION (PCV) FOR INFANTS WITH THE 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HONG KONG

dence from clinical studies concerning the relative effectiveness of Fluad® and non-adjuvanted vaccines in the over 65 population. Evidence concerning the impact of Fluad® on hospitalisation was taken from an observational study, other resource use parameters and costs from the literature. The analysis was performed from the payer perspective (direct medical costs). RESULTS: Based on the increased protective efficacy of Fluad® compared to non-adjuvanted vaccines, we estimated a reduction in cases of between 11.8% and 23.8% depending on the influenza strain circulating in the community. Using these estimates, for an attack rate of Influenza-like Illness of 5% and a discount rate of 3%, the incremental cost per life year gained (CLYG) ranged from €3103 to €23,894. In situations where there is antigenic drift (which occurs every 2–5 years), all vaccines are less effective. However, the efficacy of Fluad® falls by only 2%, whereas that of non-adjuvanted vaccines falls by 22%. With antigenic drift, the cost-effectiveness of Fluad® compared to non-adjuvanted vaccines is enhanced due to the better protective effect, and depending on the circulating strain, ranged from being cost saving to an incremental CLYG of €5709. CONCLUSION: Compared to nonadjuvanted vaccines, Fluad® is cost-effective. Since the estimated cost per life year gained is within acceptable thresholds, Fluad® should be used as the vaccine of choice in older people. * Fluad® is registered under the trade name Gripguard® in France.

PCV10 THE IMPACT OF ADEQUATE MONITORING OF LIPID LEVELS IN PATIENTS HAVING ELECTIVE PERCUTANEOUS CORONARY INTERVENTIONS IN A LOCAL PUBLIC HOSPITAL IN HONG KONG

A total of 3173 dyslipidemic patients treated with LLA and managed by general practitioners were randomly selected from a French GPs computerized database. History of CHD and number of CRF (age, family history of premature CHD, smoking, hypertension, HDL-C < 0.9mmol/L, diabetes) were documented. Percent of patients above AFSSAPS TIL and NCEP goal was defined for each level of CHD risk. RESULTS: Twentyone percent of patients had a history of CHD. Using AFSSAPS guidelines the distribution of primary prevention patients according to the number of CRFs (1, 2, 3, >3) was 1.6, 25.5, 31.7, and 20.1%, respectively. Almost 40% of CHD patients remained above TIL and the percentages of primary prevention patients above TIL varied from 3.9% for patients with 1 CRF to 46.5% for patients with > 3 CRFs (p < 0.001). Using NCEP guidelines, percentage of patients not at goal in the different CHD risk categories were significantly higher and 74.3% of CHD patients were not at LDL-C treatment goal. CONCLUSION: Seventy-three percent of patients prescribed LLA were at high CHD risk. Increasing with CHD risk level, large numbers of patients were above TIL and LDL-C treatment goal. More effective interventions are needed in lipid lowering therapy. * AFSSAPS: French Drug Agency.

PCV41 A COST ANALYSIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES USING CLOPIDOGREL IN ADDITION TO ASPIRIN IN A HONG KONG PUBLIC HOSPITAL

Results from the Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study showed that clopidogrel plus aspirin, compared to aspirin alone, reduced cardiovascular events (death, myocardial infarction, and stroke) in patients with acute coronary syndromes (ACS). Yet the acquisition cost of clopidogrel is much higher. It would therefore be worthwhile to compare the long-term cost impact of these 2 regimens. Until recently, only very few patients with ACS received clopidogrel-aspirin combination therapy in Hong Kong. Therefore, a hypothetical cohort was formed and compared to a real group of patients treated with aspirin alone. For the aspirin group, medical history was reviewed and cardiovascular and gastrointestinal events occurring in a period of 12 months after initiation of therapy were recorded. The target cost items included hospitalisation, emergency room visits, outpatient clinic visits, related medications, diagnostic tests, procedures, and surgery. For the hypothetical cohort, the probabilities/relative risks for clinical events were adopted from the CURE study. Fifty-four consecutive patients with ACS receiving aspirin therapy were identified and studied between January 1, 2001 and December 31, 2001 from a major public hospital in Hong Kong. The average cost of management per patient over the 12 month period for the aspirin group was HK

PIN11 COST-EFFECTIVENESS OF SUBSTITUTING LAMIVUDINE (LVD) WITH ENTECAVIR (ETV) IN CHRONIC HEPATITIS B (CHB) PATIENTS IN THE PUBLIC SECTOR OF HONG KONG

85,324 (US

GI4 COST-EFFECTIVENESS OF TRIPLE THERAPIES OF ESOMEPRAZOLE AND RABEPRAZOLE FOR H. PYLORI ERADICATION IN THE PUBLIC SECTOR OF HONG KONG

10,940, HK

PDB12: A PHARMACOECONOMIC ANALYSIS OF WEIGHT-REDUCTION THERAPY IN A HYPOTHETICAL COHORT OF OBESE CHINESE PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE

7.8 = 1 US

PRS11 COST ANALYSIS OF DIFFERENT PHARMACOTHERAPIES IN SUBJECTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE PUBLIC SECTOR OF HONG KONG

) versus the hypothetical cohort HK

PIN32 ECONOMIC IMPACT OF THE 10-VALENT PNEUMOCOCCAL NONTYPEABLE HEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE (PHID-CV) IN A COHORT OF NEWBORN IN HONG KONG

83,903 (US